Latest news with #ClinicalResearchasaCareOption
Business Wire
01-07-2025
- Health
- Business Wire
Javara, Cape Fear Valley Health Announce Partnership to Expand Point of Care Clinical Trial Access
WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Dedicated to expanding clinical trial access through collaboration with community-based healthcare systems, Javara today announced a new strategic partnership with Cape Fear Valley Health. Leveraging Javara's integrated teams and infrastructure, Cape Fear Valley Health — North Carolina's 8 th largest health system — will now offer clinical trial opportunities to their diverse patient population in Fayetteville, North Carolina and the surrounding areas. A multi-specialty health system with eight hospitals, an emerging medical school in partnership with Methodist University, and over 1,000 physicians, Cape Fear Valley Health currently serves eight counties in the southeastern portion of the state. Javara will employ and embed experienced clinical research staff within Cape Fear Valley Health clinics to work alongside their physicians and medical teams to scale trial operations and provide personalized care for patients electing to participate in clinical research. 'Cape Fear Valley's presence across North Carolina is vast. Their facilities and patient reach offer an unparalleled opportunity to improve population health through access to clinical trial participation,' said Javara Founder and CEO Jennifer Byrne. 'Through this partnership, we are driving forward a more inclusive clinical trial landscape — delivering access where it's needed most in the greater Fayetteville area and strengthening research efforts in oncology and beyond.' With prior research experience, Cape Fear Valley Health is perfectly positioned to maximize the impact of an integrated approach to trial delivery. Specialty and Therapeutic Capabilities will include Oncology, Cardiology, Neurology, Psychiatry, Pediatrics, Women's Health and Family Health. 'This collaboration with Javara restores a critical pathway for patients in our community to access clinical trials,' said Cape Fear Valley Health Chief Medical Officer Samual Fleishman, MD. 'Cape Fear Valley and Javara share a common goal to improve access to healthcare in underserved populations through clinical trials. This partnership enables us to again bring new interventions and cutting-edge treatments to our patients.' About Javara Javara, the leading Integrated Research Organization (IRO), partners with large healthcare organizations to deliver clinical trial access at the point of care through integrated research staff and infrastructure. The company's access to broad diverse patient populations through their trusted physician ensures clinical trials are completed with high enrollment and retention for quality data delivery. Javara's centralized resources and standardized operations provide efficiencies for accelerated study start-up and quality outcomes, so fewer obstacles stand in the way of the product approval process. As pioneers of Clinical Research as a Care Option (CRAACO), Javara is transforming healthcare and changing lives by connecting the right patients to the right trials at the right time. For more information, visit and follow the company on LinkedIn. About Cape Fear Valley Health System Cape Fear Valley Health is a 1,000+ bed, 8-hospital regional health system, with more than 1 million inpatient and outpatient visits annually. A private not-for-profit organization with 8,000 employees and more than 1,000 providers on our medical staff, it includes Cape Fear Valley Medical Center, Highsmith-Rainey Specialty Hospital, Cape Fear Valley Rehabilitation Center, Behavioral Health Care, Bladen County Hospital, Hoke Hospital, Health Pavilion North, Health Pavilion Hoke, Central Harnett Hospital and Betsy Johnson Hospital. For more information, visit
Business Wire
28-05-2025
- Business
- Business Wire
Javara Secures Series C Funding To Drive Therapeutic Expansion For Community-Forward Clinical Research
WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Javara, a leading integrated research organization (IRO) delivering clinical trials at the point of care through strategic partnership with healthcare organizations, today announced it has secured a significant growth investment in Series C funding from earlier and new community-based investors. This funding will support the expansion of both current and new healthcare partnerships and allow the company to grow into new therapeutic specialties such as Oncology, CNS, and Neurology through localized clinical research collaborations that increase patient access and amplify geographic footprint. Established in 2018, Javara was built with a vision to revolutionize the industry by accelerating access to research – for patients, biopharma companies and healthcare organizations alike. Founders Jennifer Byrne, Linda McCarty, and Amanda Wright say this funding is an essential next step in driving that mission forward. Javara's current access includes over 5 million patients across 7 states. The organization now faces the opportunity to double both patient and physician reach and develop new areas of therapeutic excellence that parallel current primary public health concerns and the rapid evolution of the clinical trials industry. 'We are extremely grateful for the privilege and opportunity this funding secures as we move into an accelerated growth era for Javara,' said Javara Founder and CEO Jennifer Byrne. 'The support of a broadened group of community-based investors will amplify our impact greatly as we work to deliver community-based clinical trial access and education for more patients across the nation.' Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Javara on the Series C funding round. Crosstree Capital Partners acted as an advisor to Javara. About Javara: Javara, the leading Integrated Research Organization (IRO), partners with large healthcare organizations to deliver clinical trial access at the point of care through integrated research staff and infrastructure. The company's access to broad diverse patient populations through their trusted physician ensures clinical trials are completed with high enrollment and retention for quality data delivery. Javara's centralized resources and standardized operations provide efficiencies for accelerated study start-up and quality outcomes, so fewer obstacles stand in the way of the product approval process. As pioneers of Clinical Research as a Care Option (CRAACO), Javara is transforming healthcare and changing lives by connecting the right patients to the right trials at the right time.
